TransMedics Group Inc. reported second-quarter revenue of $157.4 million, up 38% from a year earlier and ahead of the roughly $148 million analysts expected. Gross margin held steady at 61%, while net income rose to $34.9 million, or $0.92 a diluted share, nearly doubling Wall Street forecasts. Buoyed by the strong performance, the Andover, Massachusetts-based medical-technology firm lifted its 2025 revenue outlook to $585 million–$605 million, compared with a previous range of $565 million–$585 million. Management said adoption of the company’s Organ Care System across U.S. transplant centers and utilization of its dedicated aviation fleet continued to drive growth. Separately, TransMedics secured conditional Investigational Device Exemption clearance from the U.S. Food and Drug Administration to begin a Next-Generation OCS Lung clinical trial, positioning the company to extend its platform in lung transplantation.